NDC product
Ciclopirox olamine
NDC 45802-138 · Padagis Israel Pharmaceuticals Ltd
Key facts
| Product NDC | 45802-138 |
|---|---|
| Proprietary name | Ciclopirox olamine |
| Nonproprietary name | Ciclopirox olamine |
| Substances | CICLOPIROX OLAMINE |
| Dosage form | CREAM |
| Route | TOPICAL |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA077364 |
| Pharmacologic classes | Decreased DNA Replication [PE], Decreased Protein Synthesis [PE], Decreased RNA Replication [PE], Protein Synthesis Inhibitors [MoA] |
| Marketing start | Jul 19, 2006 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: